Stifel analyst Paul Matteis said FDA approval for BioMarin's (NASDAQ: BMRN) Voxogo (vosoritide) is a 'great win' and relief for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE